Read this company snapshot
Daily valuation snapshot
Alvotech Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $5.78
- Market capitalization (USD)
- $2,062,402,479.64
- Price / earnings (TTM)
- 73.87
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ALVO in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ALVO in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ALVO with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $5.78 |
| Market capitalization (USD) | $2,062,402,479.64 |
| Price / earnings (TTM) | 73.87 |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read ALVO's valuation metrics
Company size
Alvotech Ordinary Shares's recorded market capitalization is $2,062,402,479.64. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
ALVO's recorded P/E is 73.87: about $73.87 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Alvotech Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about ALVO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ALVO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.